News

H.C. Wainwright & Co. Research Update: “Recent Developments Underscore Clinical Progress; FUJIFILM May Exercise Option Soon; Raising Target to A$2”

Respected Wall Street analyst Dr Raghuram Selvaraju has published a further research update on Cynata, reiterating the “BUY” recommendation and raising his price target to $2.00

Download Report

This report has been prepared by H.C. Wainwright & Co., LLC and solely reflects the views of H.C. Wainwright & Co., LLC.

Any opinions, forecasts, recommendations or forward looking statements in the report reflect the judgement and assumptions of H.C. Wainwright & Co., LLC at the date of publication of the report. The Company does not endorse the findings or contents of the report, including any price target, earnings forecast or other statement about the Company’s prospects, and will not be responsible for any loss or damage arising in any way from errors, omissions or misstatements in the report or the use of, or reliance on, the report in any way.

Continue

Return To News